Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 11;39(39):5563–5570. doi: 10.1016/j.vaccine.2021.08.022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Positivity rates of each assay tested for each group at different time points. Positivity rates are presented in (%). ^aBaseline versus 2 weeks comparison (BNT162b2): p = NS (Nucleocapsid IgG); p < 0.0001 (RBD IgG, Trimeric S IgG, and nAb assays). ^b2-week versus pre-2nd dose comparison (BNT162b2): p = NS for all assays ^cAll p-values comparing baseline to pre-2nd dose (BNT162b2) vaccine were < 0.0001, except for nucleocapsid IgG (p = 1.0). ^d2-weeks versus pre-2nd dose comparison (mRNA-1273): p = NS (Nucleocapsid IgG); p < 0.01 (RBD IgG); p < 0.05 (Trimeric S IgG and nAb assays).